Reported Earlier, Altimmune Prices Oversubscribed $225M Public Offering Of 64.25M Shares At $3.00 To Fund Phase 3 MASH Trial Of Pemvidutide

Benzinga Newsdesk www.benzinga.com Neutral 76.3%